ライフサイエンスコーパス: deferasirox

1 vs deferoxamine (P = .057 for superiority of deferasirox).

2 zation more than additive (synergistic) with deferasirox.

3 hs, none of which were considered related to deferasirox.

4 effect to piroctone, 8-hydroxyquinoline, and deferasirox.

5 edications desferrioxamine, deferiprone, and deferasirox.

6 elated adverse events was comparable between deferasirox (35.4%) and deferoxamine (30.8%).

7 h placebo by LSM -235 and -337 ng/mL for the deferasirox 5 and 10 mg/kg/d groups, respectively (P < .

8 xamined the in vitro and in vivo activity of deferasirox against cells from human solid tumors.

9 Here we demonstrate that deferasirox, an iron chelator recently approved for use

10 Two new oral agents, deferasirox and deferiprone, have become available in th

11 sed in patients receiving different doses of deferasirox and the comparator deferoxamine.

12 udy following a single 35-mg/kg dose of oral deferasirox; and pharmacogenomic analysis.

13 ic iron imaging and the availability of oral deferasirox are expected to improve clinical care, but t

14 rculosis, malaria), broader investigation of deferasirox as an antiinfective treatment is warranted.

15 on the safety and efficacy results, starting deferasirox at 10 mg/kg/day appears to be most appropria

16 randomized clinical trial demonstrates that deferasirox at 20 to 30 mg/kg/d can maintain or improve

17 ed 30% sickle hemoglobin (HbS) and tolerated deferasirox at 28.2 +/- 6.0 mg/kg/d.

18 ots are consistent with ELT donating iron to deferasirox at clinically relevant concentrations.

19 tained with deferiprone, desferrioxamine, or deferasirox at similar iron-binding equivalents.

20 T scavenges iron citrate species faster than deferasirox, but rapidly donates the chelated iron to de

21 CORDELIA demonstrated the noninferiority of deferasirox compared with deferoxamine for myocardial ir

22 y to characterize the safety and efficacy of deferasirox, comprising a core and an extension phase (e

23 ox, but rapidly donates the chelated iron to deferasirox, consistent with a shuttling mechanism.

24 Deferasirox demonstrated similar activity at inhibiting

25 Deferasirox (DFX) monotherapy is effective for reducing

26 , deferoxamine (DFO), deferiprone (DFP), and deferasirox (DFX), including their efficacy, patient acc

27 esented by Pennell and colleagues shows that deferasirox (DFX; Exjade, Novartis) is not inferior to d

28 At a deferasirox dose of 20 mg/kg per day, neutral or negativ

29 In the cardiac iron reduction arm, the mean deferasirox dose was 32.6 mg/kg per day.

30 ising ferritin trend or rising liver iron on deferasirox doses > 30 mg/kg per day) with control trans

31 All patients initially received deferasirox doses of 30 to 40 mg/kg per day.

32 patients were enrolled and received starting deferasirox doses of 5 (n = 11), 10 (n = 15), or 15 (n =

33 Deferasirox doses of 5, 10, and 15 mg/kg/day can reduce

34 The means +/- SD of the actual deferasirox doses received over the duration of the stud

35 Deferasirox effectively chelated iron from Rhizopus oryz

36 The once-daily, oral iron chelator, deferasirox (Exjade) may provide an alternative treatmen

37 The predominant chelator currently used is deferasirox, followed by deferoxamine and then combinati

38 After receiving deferasirox for 48 weeks, median serum ferritin levels d

39 omparison data on the efficacy and safety of deferasirox for myocardial iron removal in transfusion d

40 jective was to demonstrate noninferiority of deferasirox for myocardial iron removal, assessed by cha

41 ic mean (Gmean) myocardial T2* improved with deferasirox from 11.2 milliseconds at baseline to 12.6 m

42 Fe/g dw, P < .001) for the 5 and 10 mg/kg/d deferasirox groups, respectively (baseline values [means

43 Patients with inadequate response to deferasirox had significantly lower systemic drug exposu

44 The oral iron chelator deferasirox has become commercially available in many co

45 inoyl hydrazone (311), and the iron chelator deferasirox (ICL670) inhibits HIV-1 transcription.

46 a) trial assessed the efficacy and safety of deferasirox in iron-overloaded NTDT patients.

47 er trial assessed the safety and efficacy of deferasirox in low- or intermediate-1-risk myelodysplast

48 The efficacy of deferasirox in reducing or preventing cardiac iron overl

49 ed trial of oral iron chelation therapy with deferasirox in this population.

50 sing data from the 1-year phase III study of deferasirox, including volumes of transfused red blood c

51 We demonstrated that deferasirox increased expression of the metastasis suppr

52 ent received monthly transfusions plus daily deferasirox iron chelation.

53 Collectively, we demonstrate that deferasirox is an orally effective antitumor agent again

54 Deferasirox is an orally effective iron (Fe) chelator cu

55 This prospective study shows that deferasirox is effective in removing and preventing myoc

56 mens for inadequately responding patients to deferasirox must be determined.

57 been no studies to investigate the effect of deferasirox on these types of tumors in vivo.

58 djustment, reductions in LIC after 1 year of deferasirox or deferoxamine therapy correlated with tran

59 red upon administration of the iron chelator deferasirox or hyperexpression of Fpn1 or Nrf2.

60 atio to starting doses of 5 or 10 mg/kg/d of deferasirox or placebo.

61 tions include combination lipid polyene plus deferasirox or posaconazole therapy.

62 We performed a prospective study of oral deferasirox pharmacokinetics (PK), comparing 10 transfus

63 c uptake and excretion of chelate; a 24-hour deferasirox PK study following a single 35-mg/kg dose of

64 However, deferasirox potently inhibited DMS-53 xenograft growth i

65 Deferasirox reduces serum ferritin and LPI in transfusio

66 aring 10 transfused patients with inadequate deferasirox response (rising ferritin trend or rising li

67 dotic or neutropenic mice with mucormycosis, deferasirox significantly improved survival and decrease

68 induced by treatment with the iron chelator deferasirox significantly protected flies infected with

69 mized study showing that iron chelation with deferasirox significantly reduces iron overload in NTDT

70 Most importantly, deferasirox synergistically improved survival and reduce

71 was a prospective, randomized comparison of deferasirox (target dose 40 mg/kg per day) vs subcutaneo

72 uating response of cardiac and liver iron to deferasirox therapy for 18 months.

73 support clinical investigation of adjunctive deferasirox therapy to improve the poor outcomes of muco

74 we treated the patient with off-label use of deferasirox to maintain iron deficiency, with successful

75 Deferasirox treatment also enhanced the host inflammator

76 s deferoxamine alone, and the equivalence of deferasirox versus deferoxamine.

77 argin of 0.9, establishing noninferiority of deferasirox vs deferoxamine (P = .057 for superiority of

78 The starting dose of deferasirox was 20 mg/kg/d, with dose escalation up to 4

79 Monotherapy with deferasirox was effective in patients with mild to moder

80 Furthermore, deferasirox was generally similar or slightly more effec

81 The novel oral chelator deferasirox was recently approved by the Food and Drug A

82 Deferasirox was shown to reduce iron overload in patient

83 To understand the antitumor activity of deferasirox, we investigated its effect on the expressio

84 ne (CPX), piroctone, 8-hydroxyquinoline, and deferasirox-were also shown to efficiently chelate intra